Home Tags Biotech

Tag: Biotech

Proteus makes 'smart pills' embedded with sensors that tell your doctor when you've taken your medication. It announced a clinical trial in cancer on Thursday.

We got a look at the pitch deck of buzzy Silicon Valley health-tech startup Sempre Health. It reveals how a $4 billion industry is ripe for disruption...

Startup Sempre Health has raised $10.5 million to take aim at a well-known problem with people and their pills: they don't always take them.

Dispensed: Career advice from BI’s young healthcare leaders, a wild week for biotechs, and a list of white-hot AI startups

Welcome to Dispensed, our weekly dispatch of healthcare, biotech, and pharma news from Business Insider.

Dispensed: A big week for digital health IPOs, what happens when a $2.1 million drug can’t get to the kids who need it, and what a top health-te...

Welcome to Dispensed, our weekly dispatch of healthcare, biotech, and pharma news from Business Insider.

Biogen climbs as profits surge 72%, prompting the firm to boost 2019 guidance

The company is down about 35% over the last 12 months, with a failed Alzheimer's trial driving investors away in March.
The microbiome testing company uBiome has come under scrutiny after an FBI raid.

Dispensed: Oscar’s first moves in Medicare Advantage, uBiome’s new board members, and Novartis’ CEO’s commitment to wearing je...

Welcome to Dispensed, our weekly dispatch of healthcare, biotech, and pharma news from Business Insider.

Belgian biotech Galapagos surges after Gilead sinks another $5.1 billion into the firm

The deal gives Gilead rights outside Europe to the Belgian biotech company's drugs in development. Galapagos has six treatments in human testing.

Dispensed: Pharma’s next big megamerger, a string of healthcare IPOs, and why the CEO of Clover Health regrets setting up shop in Silicon Valley...

Welcome to Dispensed, our weekly dispatch of healthcare, biotech, and pharma news from Business Insider.
Chad Robins, the CEO of Adaptive Biotechnologies.

Forget Beyond Meat — Adaptive Biotechnologies just spiked 95% in its public trading debut, marking the year’s best post-IPO pop

The Seattle-based biotech, which provides tests used to diagnose and treat diseases, began trading shortly after noon Eastern Time under "ADPT."

Dispensed: Young blood startup is back, a scoop about CityMD, and telling remarks from Merck’s CEO

Welcome to Dispensed, our weekly dispatch of healthcare, biotech, and pharma news from Business Insider.

Array BioPharma spikes more than 50% after Pfizer shells out $11 billion for the cancer-drug developer

Pfizer's blockbuster deal for Array BioPharma is the latest in a growing list of M&A deals to take place in the cancer-treatment space this year.